title: Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone Treatment.
abstract: Tumors arising at the lacrimal sac are extremely rare, as a limited number of cases have been reported worldwide. They are commonly primary and the majority of them are malignant and epithelial in origin. Adenocarcinomas account for a small percentage of these tumors. Treatment of local disease mainly includes complete surgical resection. However, metastatic disease has a poor prognosis and the development of new treatment strategies is highly important. Research efforts mainly focus on the identification of molecular targets for therapy. Herein, we describe for the first time a case of a patient with an androgen receptor expressing adenocarcinoma of the lacrimal sac that had an impressive response to abiraterone.
authors.affiliation: Oncology Unit, 2nd Department of Internal Medicine - Propaedeutic, Attikon University Hospital , Haidari , Greece.
authors.forename: Elena
authors.initials: E
authors.lastname: Vagia
authors.affiliation: Oncology Unit, 2nd Department of Internal Medicine - Propaedeutic, Attikon University Hospital , Haidari , Greece.
authors.forename: Panagiota
authors.initials: P
authors.lastname: Economopoulou
authors.affiliation: 2nd Department of Radiology, Attikon University Hospital , Haidari , Greece.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Oikonomopoulos
authors.affiliation: Department of Oncology, Hygeia Hospital , Athens , Greece.
authors.forename: Ilias
authors.initials: I
authors.lastname: Athanasiadis
authors.affiliation: Oncology Unit, 2nd Department of Internal Medicine - Propaedeutic, Attikon University Hospital , Haidari , Greece.
authors.forename: George
authors.initials: G
authors.lastname: Dimitriadis
authors.affiliation: Oncology Unit, 2nd Department of Internal Medicine - Propaedeutic, Attikon University Hospital , Haidari , Greece.
authors.forename: Amanda
authors.initials: A
authors.lastname: Psyrri
keywords: abiraterone; adenocarcinoma; androgen receptor; lacrimal sac; molecular target